Lynx1 Capital Management LP 13D and 13G filings for C4 Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 09:01 am Purchase | 2024-09-30 | 13G | C4 Therapeutics, Inc. CCCC | Lynx1 Capital Management LP | 6,880,527 9.900% | 3,746,131 (+119.52%) | Filing |
| 2024-02-14 09:21 am Purchase | 2023-12-31 | 13G | C4 Therapeutics, Inc. CCCC | Lynx1 Capital Management LP | 3,134,396 6.400% | 12,177 (+0.39%) | Filing |
| 2023-11-13 4:55 pm Purchase | 2023-11-01 | 13G | C4 Therapeutics, Inc. CCCC | Lynx1 Capital Management LP | 3,122,219 6.300% | 3,122,219 (New Position) | Filing |